Identifying a Csmd3 + Microglial Subpopulation that Drives Cold‐to‐Hot Transition and Immune‐Cure in Glioblastoma
Open Access
- 20 July 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 13 (57) , e76690
Abstract
Glioblastoma (GBM) is immunologically cold and responds poorly to immune‐based therapies owing to its highly heterogeneous and immunosuppressive tumor microenvironment (TME). However, strategies to achieve a cold‐to‐hot transition remain elusive, and suitable research models are still lacking. Here, TME profiling classifies our refractory G422 TN ‐GBM model as the TME Med (heterogeneous immune populations, “cold”) subtype of human GBM, which can be shifted toward the TME High (immune‐high, “hot”) subtype by inhibiting TGF‐β signaling. In the multi‐drug regimen, only αTGF‐β combining temozolomide chemoradiotherapy and αPD‐1 achieves immune‐cure (ICu, passing tumor rechallenge, 12.5%). ICu screening reveals a newly identified Csmd3 + microglial subset with innate immune memory potential, which likely initiates durable anti‐GBM immune memory and closely associates with effective GBM therapy and favorable prognosis. MG OE• Csmd3 , BV2 ( Csmd3 ‐overexpressed microglial BV2) elicit robust anti‐GBM effects and achieve a notably 100% tumor rechallenge success in G422 TN ‐GBM mice via promoting TME Med ‐to‐TME High remodeling. Taken together, our findings identify an immunologically cold TME Med GBM mouse model and provide a proof‐of‐concept for microglia‐based TME reprogramming and cell therapy in GBM.Keywords
Funding Information
- National Natural Science Foundation of China (82173197)
- National Natural Science Foundation of China (32270715)
- National Natural Science Foundation of China (32470712)
- National Natural Science Foundation of China (32421003)
This publication has 102 references indexed in Scilit:
- Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structuresCancer Cell, 2025
- GDF11 Regulates M1 and M2 Polarization of BV2 Microglial Cells via p38 MAPK Signaling PathwayMolecular Neurobiology, 2025
- Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsCancer Cell, 2024
- Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalizationCancer Cell, 2024
- rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic CellsAdvanced Science, 2024
- Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapyAnnals of Oncology, 2022
- Bifurcation of signalling in human innate immune pathways to NF-kB and IRF family activationBiochemical Pharmacology, 2022
- Complex heatmap visualizationiMeta, 2022
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Mannose synergizes with chemoradiotherapy to cure cancer via metabolically targeting HIF‐1 in a novel triple‐negative glioblastoma mouse modelClinical and Translational Medicine, 2020